Table 2 Baseline characteristics of the study cohort, as a group and according to anti-Ro52/TRIM21 antibody status

Age, years

55.42

12.04

57.16

11.45

54.98

12.16

1.02 (1.00, 1.03)

0.0481

Female, %

833

86.50%

175

90.21%

658

85.57%

NS

White, %

816

84.74%

160

82.47%

656

85.31%

NS

Disease duration, years

11.04

9.47

11.29

9.55

10.98

9.46

NS

Disease subsets, %

NS

   Limited disease

563

59.26%

121

62.69%

442

58.39%

   Diffuse disease

356

37.47%

69

35.75%

287

37.91%

   Sine scleroderma

31

3.26%

3

1.55%

28

3.70%

Modified Rodnan skin score (range, 0-51)

10.02

9.47

9.68

8.53

10.11

9.69

NS

Swollen-joint count

(range, 0-28)

0.91

3.34

1.07

4.26

0.87

3.07

NS

Number of GI symptoms (range 0-14)

4.17

3.13

4.27

3.30

4.14

3.09

NS

Inflammatory myositis, %

103

11.48%

21

11.54%

82

11.47%

NS

Thrombosis, %

29

3.06%

7

3.65%

22

2.91%

NS

Scleroderma renal crisis, %

42

4.44%

7

3.65%

35

4.64%

NS

Interstitial lung disease, %

342

36.19%

85

44.27%

257

34.13%

1.53 (1.11, 2.12)

0.0091

Pulmonary hypertension,%

96

11.72%

26

15.38%

70

10.77%

NS

Overlap with SLE, %

30

3.19%

8

4.23%

22

2.93%

NS

Overlap with Sjögren, %

63

6.70%

18

9.52%

45

5.98%

NS

Overlap with RA, %

30

3.19%

8

4.23%

22

2.93%

NS

Overlap with MCTD, %

20

2.13%

7

3.70%

13

1.73%

NS

Overlap with PM/DM, %

36

3.83%

12

6.35%

24

3.19%

2.06 (1.01, 4.19)

0.0431

Overlap syndrome, %

143

15.18%

41

21.58%

102

13.56%

1.75 (1.17, 2.63)

0.0059